RLAY RELAY THERAPEUTICS INC Product Launches 8-K Filing 2024 - Clinical Data Update Relay Therapeutics announced updated interim clinical data for RLY-2608, showing a median progression-free survival of 9.2 months in patients with advanced breast cancer, and plans to discuss these results in a conference call on December 11, 2024.Get access to all SEC 8-K filings of the RELAY THERAPEUTICS INC